Skip to main content
. 2021 Mar 16;27(5-6):336–350. doi: 10.1089/ten.tea.2020.0092

FIG. 6.

FIG. 6.

Comparative analysis for cell and tissue-engineered therapies in Europe of musculoskeletal/rheumatological subindications from 2010 to 2017 for two consecutive years, sorted by mode of processing (A) donor type, (B) expansion, (C) transduction, (D) Sorting, (E) delivery mode, and (F) clinical procedure. Data used for this chart were derived from this study and five previous reports (1–5).